Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.60 |
| ▸ | MAPT | P10636 | 4/20 | 0.60 |
| ▸ | HPGD | P15428 | 4/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.53 |
| ▸ | ESRRB | O95718 | 1/20 | 0.51 |
| ▸ | ESR1 | P03372 | 1/20 | 0.51 |
| ▸ | ESRRA | P11474 | 1/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | ACP1 | P24666 | 1/20 | 0.51 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.50 |
| ▸ | DHODH | Q02127 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30592743 | 0.88 | DHODH (0.58) | ALDH1A1KDM4EMAPTHPGDMEN1 | |
| SCHEMBL29793367 | 0.88 | ACHE (0.61) | ALDH1A1KDM4EHPGDMEN1KMT2A | |
| SCHEMBL785473 | 0.88 | ACHE (0.61) | ALDH1A1KDM4EHPGDMEN1KMT2A | |
| SCHEMBL20854991 | 0.87 | ADORA1 (0.49) | ALDH1A1KDM4EMAPTHPGDMEN1 | |
| SCHEMBL6534331 | 0.86 | NPC1 (0.54) | KDM4EMAPTMEN1KMT2AL3MBTL1 | |
| SCHEMBL6534520 | 0.85 | ADORA1 (0.59) | ALDH1A1KDM4EMAPTHPGDMEN1 | |
| SCHEMBL10866017 | 0.85 | LMNA (0.64) | ALDH1A1KDM4EMAPTHPGDMEN1 | |
| SCHEMBL6534291 | 0.85 | ESRRB (0.49) | ALDH1A1KDM4EMAPTHPGDMEN1 | |
| SCHEMBL6534253 | 0.84 | TP53 (0.47) | ALDH1A1KDM4EMAPTHPGDMEN1 | |
| SCHEMBL6534406 | 0.84 | NPC1 (0.56) | ALDH1A1KDM4EMAPTHPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10179770-B2 | Quinolines derivatives as novel anticancer agents | GENOSCIENCE PHARMA (FR) | 2019-01-15 | — | — | US | disclosed |
| US-10179770-B2 | Quinolines derivatives as novel anticancer agents | GENOSCIENCE PHARMA (FR) | 2019-01-15 | — | — | US | disclosed |
| CN-105102442-B | Quinoline as anticarcinogen | 基因科学医药公司 | 2018-11-09 | — | — | CN | disclosed |
| EP-2976333-B1 | QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS | GENOSCIENCE PHARMA SAS (FR) | 2018-08-08 | — | — | EP | disclosed |
| EP-2976333-B1 | QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS | GENOSCIENCE PHARMA SAS (FR) | 2018-08-08 | — | — | EP | disclosed |
| US-20160280653-A1 | QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS | GENOSCIENCE PHARMA (FR) | 2016-09-29 | — | — | US | disclosed |
| US-20160280653-A1 | QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS | GENOSCIENCE PHARMA (FR) | 2016-09-29 | — | — | US | disclosed |
| US-20160280653-A1 | QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS | GENOSCIENCE PHARMA (FR) | 2016-09-29 | — | — | US | disclosed |
| EP-2976333-A1 | QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS | Genoscience Pharma SAS (FR) | 2016-01-27 | — | — | EP | disclosed |
| CN-105102442-A | Quinolines derivatives as novel anticancer agents | GENOSCIENCE PHARMA | 2015-11-25 | — | — | CN | disclosed |
| CN-1181059-C | Quinoline-4-base deviative I | - | 2004-12-22 | — | — | CN | disclosed |
| EP-1088818-B1 | Quinolin-4-yl derivatives | HOFFMANN LA ROCHE (CH) | 2004-11-03 | — | — | EP | disclosed |
| EP-1377554-A1 | ANTAGONISM OF IMMUNOSTIMULATORY CPG-OLIGONUCLEOTIDES BY 4-AMINOQUINOLINES AND OTHER WEAK BASES | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2004-01-07 | — | — | EP | disclosed |
| US-6479504-B1 | USED IN PREVENTATIVE AND THERAPEUTIC TREATMENTS OF AUTOIMMUNE DISEASES AND PHENOMENA, TRANSPLANT REJECTION SUCH AS HOST-VERSUS-GRAFT DISEASE, AND SEPSIS | THE UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2002-11-12 | — | — | US | disclosed |
| US-6440995-B1 | NMDA-RECEPTOR SUBTYPE SELECTIVE BLOCKERS | HOFFMAN-LA ROCHE INC. | 2002-08-27 | — | — | US | disclosed |
| CN-1290698-A | Quinoline-4-base deviative I | HOFFMANN LA ROCHE (CH) | 2001-04-11 | — | — | CN | disclosed |
| EP-1088818-A1 | Quinolin-4-yl derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-04 | — | — | EP | disclosed |
| WO-2000076982-A1 | ANTAGONISM OF IMMUNOSTIMULATORY CPG-OLIGONUCLEOTIDES BY 4-AMINOQUINOLINES AND OTHER WEAK BASES | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2000-12-21 | — | — | WO | disclosed |
| EP-0168812-A1 | 4-Amino-2-phenyl quinolines, methods and intermediates for their preparation and medicaments containing them | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1986-01-22 | — | — | EP | disclosed |
| US-4560692-A | ANTICONVULSANTS OR ANXIOLYTIC AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1985-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10179770-B2 | Quinolines derivatives as novel anticancer agents | NQO2, MKI67, NQO1 | ALDH1A1 1658/4885KDM4E 979/4885MAPT 3131/4885 |
| US-20160280653-A1 | QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS | NQO2, MKI67, NQO1 | ALDH1A1 1658/4885KDM4E 979/4885MAPT 3131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.